Pfizer is offloading a scrapped Seagen ADC to Medicus Pharma under an arrangement that could reach $1 billion-plus, according to the report. The move continues the broader reshaping of antibody-drug conjugate portfolios as companies prune assets and redeploy capital toward higher-conviction programs. For Medicus, the co-development rights provide an opportunity to apply its development strategy to a pre-existing ADC framework, potentially accelerating time-to-clinic depending on regulatory and data requirements. The transaction underscores ongoing rebalancing in ADC pipelines amid competitive development cycles.